First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Accent Therapeutics
Vividion Therapeutics, Inc.
Nimbus Therapeutics
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
Marengo Therapeutics, Inc.
Fate Therapeutics
Incyte Corporation
Incyte Corporation